LEARNING PROGRAM REGISTRATION

BACK About the Program

Join Dr. Jonathan Silverberg for an engaging accredited evening featuring international expertise and real world clinical perspectives on the management of moderate-to-severe atopic dermatitis. Interactive sessions pair self‑assessment with expert insights on AD treatments, IL‑13 pathways, and biologic differentiation, plus personalized feedback to support improved patient outcomes.

Program Learning Objectives

  • Explain the root causes of AD inflammation and how these are targeted by advanced therapies
  • Describe key findings and share clinical pearls from recent clinical trials and real-world experience to differentiate advanced therapies in moderate-to-severe AD
  • Develop strategies for timely initiation of advanced treatment for moderate-to-severe AD to optimize clinical outcomes, reduce disease burden and reduce risk of relapse
  • Evaluate and refine their approach to individualized treatment of moderate-to-severe AD through evidence-based decision-making

June 1st, 2026

Arrival
6:30 pm PDT
Presentation Start
7:00 pm PDT
Presentation End
8:30 pm PDT
Add to Calendar 06/01/2026 07:00 pm 06/01/2026 08:30 pm America/Vancouver Cross-Border Perspectives in Atopic Dermatitis

Thank you for your interest in the presentation of the program titled Cross-Border Perspectives in Atopic Dermatitis.

SPEAKER: Jonathan Silverberg, MD, PhD, MPH, FAAD
MODERATOR: Chih-ho Hong, MD, FRCPC

You can join the event either in person or virtually.

IN-PERSON ATTENDANCE:
Westin Bayshore, 1601 Bayshore Dr., Vancouver, BC, V6G 2V4

CONNECTION INSTRUCTIONS:
Click here to join the meeting on Zoom: https://us02web.zoom.us/webinar/register/WN_PCtxc0T1TBmm4r4lml2RxQ
Meeting ID: 818 2337 3222
Password: 163191

*Detailed connection instructions are provided further below.

Learning Objectives:
Upon completion of this program, participants will be better able to:
  • Explain the root causes of AD inflammation and how these are targeted by advanced therapies
  • Describe key findings and share clinical pearls from recent clinical trials and real-world experience to differentiate advanced therapies in moderate-to-severe AD
  • Develop strategies for timely initiation of advanced treatment for moderate-to-severe AD to optimize clinical outcomes, reduce disease burden and reduce risk of relapse
  • Evaluate and refine their approach to individualized treatment of moderate-to-severe AD through evidence-based decision-making
This program is brought to you by The CPD Network, a non-profit organization. It has received an educational grant and in-kind support from Eli Lilly Canada Inc.

You will receive a reminder by email in the days prior to the event.

For any questions related to this hybrid, please contact implementation@livagency.ca.

 Westin Bayshore 1601 Bayshore Dr. Vancouver, BC V6G 2V4 Virtual: https://us02web.zoom.us/webinar/register/WN_PCtxc0T1TBmm4r4lml2RxQ

Westin Bayshore
1601 Bayshore Dr.
Vancouver, BC V6G 2V4

Speaker(s) Jonathan Silverberg, MD, PhD, MPH, FAAD
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Moderator(s) Chih-ho Hong, MD, FRCPC
Clinical Associate Professor, Department of Dermatology and Skin Science, University of British Columbia
Principal Investigator, Dr. Chih-ho Hong Medical Inc., a member of Probity Medical Research
Vancouver, BC






This program is brought to you by The CPD Network, a non-profit organization. It has received an educational grant and in-kind support from Eli Lilly Canada Inc.